Atria Investments Inc Invests $122,000 in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Atria Investments Inc purchased a new position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,807 shares of the company’s stock, valued at approximately $122,000. Atria Investments Inc owned about 0.15% of Global X Genomics & Biotechnology ETF as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. One Capital Management LLC increased its position in shares of Global X Genomics & Biotechnology ETF by 22.1% during the second quarter. One Capital Management LLC now owns 680,311 shares of the company’s stock valued at $7,102,000 after purchasing an additional 123,339 shares during the period. Oppenheimer Asset Management Inc. grew its position in Global X Genomics & Biotechnology ETF by 10.2% in the second quarter. Oppenheimer Asset Management Inc. now owns 67,712 shares of the company’s stock valued at $707,000 after acquiring an additional 6,260 shares during the period. Corrado Advisors LLC grew its position in Global X Genomics & Biotechnology ETF by 3.0% in the third quarter. Corrado Advisors LLC now owns 64,224 shares of the company’s stock valued at $723,000 after acquiring an additional 1,894 shares during the period. Sanctuary Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF in the second quarter valued at $590,000. Finally, Archford Capital Strategies LLC grew its position in Global X Genomics & Biotechnology ETF by 59.1% in the second quarter. Archford Capital Strategies LLC now owns 36,871 shares of the company’s stock valued at $385,000 after acquiring an additional 13,703 shares during the period. 56.95% of the stock is currently owned by institutional investors.

Global X Genomics & Biotechnology ETF Price Performance

Shares of NASDAQ:GNOM opened at $10.08 on Monday. The business’s fifty day moving average price is $10.75 and its two-hundred day moving average price is $10.85. Global X Genomics & Biotechnology ETF has a fifty-two week low of $9.52 and a fifty-two week high of $12.53. The stock has a market capitalization of $73.68 million, a price-to-earnings ratio of -4.31 and a beta of 1.03.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.